On Tuesday, Nektar Therapeutics (NASDAQ: NKTR) opened lower -3.72% from the last session, before settling in for the closing price of $0.81. Price fluctuations for NKTR have ranged from $0.54 to $1.93 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -2.93% annually for the last half of the decade. Company’s average yearly earnings per share was noted 50.60% at the time writing. With a float of $177.74 million, this company’s outstanding shares have now reached $184.46 million.
In an organization with 137 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 67.8%, operating margin of -145.96%, and the pretax margin is -180.71%.
Nektar Therapeutics (NKTR) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Nektar Therapeutics is 3.64%, while institutional ownership is 74.36%. The most recent insider transaction that took place on Dec 23 ’24, was worth 30,062. In this transaction Chief Legal Officer of this company sold 33,402 shares at a rate of $0.90, taking the stock ownership to the 351,892 shares. Before that another transaction happened on Dec 24 ’24, when Company’s Chief Legal Officer sold 16,560 for $0.89, making the entire transaction worth $14,738. This insider now owns 335,332 shares in total.
Nektar Therapeutics (NKTR) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.21 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 50.60% per share during the next fiscal year.
Nektar Therapeutics (NASDAQ: NKTR) Trading Performance Indicators
Check out the current performance indicators for Nektar Therapeutics (NKTR). In the past quarter, the stock posted a quick ratio of 4.24. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.54.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.84, a number that is poised to hit -0.14 in the next quarter and is forecasted to reach -0.77 in one year’s time.
Technical Analysis of Nektar Therapeutics (NKTR)
Let’s dig in a bit further. During the last 5-days, its volume was 1.18 million. That was inferior than the volume of 1.47 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 9.80%. Additionally, its Average True Range was 0.07.
During the past 100 days, Nektar Therapeutics’s (NKTR) raw stochastic average was set at 1.39%, which indicates a significant decrease from 5.19% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 28.32% in the past 14 days, which was lower than the 65.67% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.9764, while its 200-day Moving Average is $1.2429. However, in the short run, Nektar Therapeutics’s stock first resistance to watch stands at $0.8100. Second resistance stands at $0.8400. The third major resistance level sits at $0.8600. If the price goes on to break the first support level at $0.7600, it is likely to go to the next support level at $0.7400. The third support level lies at $0.7100 if the price breaches the second support level.
Nektar Therapeutics (NASDAQ: NKTR) Key Stats
There are currently 184,458K shares outstanding in the company with a market cap of 143.66 million. Presently, the company’s annual sales total 90,120 K according to its annual income of -276,060 K. Last quarter, the company’s sales amounted to 24,120 K and its income totaled -37,060 K.
